Is it time to rethink perioperative immunotherapy in resectable
gastric and gastroesophageal junction (GEJ) cancers? See the latest
data and expert takeaways.
Credit available for this activity expires: 7/18/2026
Earn Credit / Learning Objectives & Disclosures: